跳至主要内容
临床试验/NCT06154902
NCT06154902进行中(未招募)不适用

ABE-DESCART Study: Characterization and Outcomes of Patients With Relapsed and Refractory Multiple Myeloma Eligible for Treatment or Treated With Abecma© (Idecabtagene Vicleucel) in Real World Setting in France. A Database Analysis Based on the DESCAR-T Registry

Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2022年7月29日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
350
试验地点
1
主要终点
Overall survival

研究概览

简要总结

The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM) who are eligible for treatment with, or have been treated with, idecabtagene vicleucel. This study will use both prospective and retrospective data from the DESCAR-T registry database.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with RRMM registered in the DESCAR-T registry and eligible for treatment or treated with idecabtagene vicleucel

排除标准

  • Not registered with the social security in France

研究组 & 干预措施

Treated with idecabtagene vicleucel

干预措施: Idecabtagene vicleucel (Drug)

Eligible for idecabtagene vicleucel

Eligible for idecabtagene vicleucel treatment but not treated

干预措施: Not treated (Other)

结局指标

主要结局

Overall survival

时间窗: 15 years

次要结局

未报告次要终点

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Real-World Outcomes in Relapsed/Refractory Multiple... | 临床试验